These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Renin and the therapy of hypertension. Guthrie GP; Genest J; Kuchel O Annu Rev Pharmacol Toxicol; 1976; 16():287-308. PubMed ID: 779617 [No Abstract] [Full Text] [Related]
4. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone? Mahmud A; Mahgoub M; Hall M; Feely J Am J Hypertens; 2005 Dec; 18(12 Pt 1):1631-5. PubMed ID: 16364838 [TBL] [Abstract][Full Text] [Related]
5. [The effect of alpha methyldopa and spironolactone on angiotensin sensitivity in man]. Káldor A; Kállay K; Sebestyén K; Alexits K Orv Hetil; 1972 Jan; 113(1):23-4. PubMed ID: 4333395 [No Abstract] [Full Text] [Related]
7. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders. Krum H; Gilbert RE J Hypertens; 2007 Jan; 25(1):25-35. PubMed ID: 17143168 [TBL] [Abstract][Full Text] [Related]
8. Antihypertensive persistence and drug class. Marentette MA; Gerth WC; Billings DK; Zarnke KB Can J Cardiol; 2002 Jun; 18(6):649-56. PubMed ID: 12107422 [TBL] [Abstract][Full Text] [Related]
9. Hypertension medications and dental considerations. Wynn RL Gen Dent; 2000; 48(2):126-31. PubMed ID: 11199569 [No Abstract] [Full Text] [Related]
10. [Comparison between the effects of angiotensin-converting enzyme inhibitors and angiotensin II antagonists]. Asmar R; Madonna O; Brisac AM; Benetos A; Laurent S Therapie; 1998; 53(3):253-70. PubMed ID: 9773125 [TBL] [Abstract][Full Text] [Related]
12. [Historical perspective of renin-angiotensin system blocking in the treatment of arterial hypertension]. Coca A; Redón J Med Clin (Barc); 1996 Mar; 106(12):457-9. PubMed ID: 8656731 [No Abstract] [Full Text] [Related]
13. Spironolactone for the treatment of isolated systolic hypertension. Yarows SA Am J Hypertens; 2004 Mar; 17(3):284. PubMed ID: 15001208 [No Abstract] [Full Text] [Related]
14. Aliskiren combined with losartan in diabetes and nephropathy. Lindner T N Engl J Med; 2008 Sep; 359(10):1068-9; author reply 1069-70. PubMed ID: 18777612 [No Abstract] [Full Text] [Related]
15. [Medical angiotensin II-receptor blockade in hypertension and heart failure]. van Zwieten PA; Lie KI Ned Tijdschr Geneeskd; 1995 Jul; 139(30):1529-33. PubMed ID: 7675129 [No Abstract] [Full Text] [Related]
16. Role of renin and aldosterone suppression in the antihypertensive mechanism of clonidine. Niarchos AP; Baer L; Radichevich I Am J Med; 1978 Oct; 65(4):614-8. PubMed ID: 707522 [No Abstract] [Full Text] [Related]
17. Renin inhibition: should it supplant ACE inhibitors and ARBS in high risk patients? Gaddam KK; Oparil S Curr Opin Nephrol Hypertens; 2008 Sep; 17(5):484-90. PubMed ID: 18695389 [TBL] [Abstract][Full Text] [Related]
18. [Therapeutic possibilities for the inhibition of the renin-angiotensin-aldosterone system]. Abrahám G; Légrády P Orv Hetil; 2003 May; 144(18 Suppl 1):892-5. PubMed ID: 12785232 [TBL] [Abstract][Full Text] [Related]
19. Hypertension in older patients: what drugs to use and when. Caris TN Geriatrics; 1982 Mar; 37(3):38-43. PubMed ID: 7067974 [No Abstract] [Full Text] [Related]
20. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension due to primary aldosteronism: a case for exclusion. Bubbar CD; Blackburn DF; Wilson MP; Wilson TW Ann Pharmacother; 2007 Jan; 41(1):129-32. PubMed ID: 17179189 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]